Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Compass Pathways Plc ADR (CMPS)

Compass Pathways Plc ADR (CMPS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 793,100
  • Shares Outstanding, K 96,017
  • Annual Sales, $ 0 K
  • Annual Income, $ -155,120 K
  • EBIT $ -182 M
  • EBITDA $ -181 M
  • 60-Month Beta 1.92
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 19.47

Options Overview Details

View History
  • Implied Volatility 100.10% (-15.74%)
  • Historical Volatility 104.74%
  • IV Percentile 13%
  • IV Rank 10.76%
  • IV High 287.30% on 06/20/25
  • IV Low 77.53% on 11/25/25
  • Expected Move (DTE 28) 1.62 (19.55%)
  • Put/Call Vol Ratio 4.86
  • Today's Volume 11,766
  • Volume Avg (30-Day) 4,715
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 64,620
  • Open Int (30-Day) 62,080
  • Expected Range 6.65 to 9.88

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 13 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.41
  • Number of Estimates 4
  • High Estimate -0.29
  • Low Estimate -0.47
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +34.92%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.66 +43.69%
on 02/05/26
8.90 -8.54%
on 02/18/26
+0.83 (+11.35%)
since 01/20/26
3-Month
4.90 +66.12%
on 12/03/25
8.90 -8.54%
on 02/18/26
+2.94 (+56.54%)
since 11/20/25
52-Week
2.25 +261.78%
on 06/23/25
8.90 -8.54%
on 02/18/26
+3.60 (+79.30%)
since 02/20/25

Most Recent Stories

More News
Compass Pathways Announces Pricing of $150 Million Public Offering

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American...

CMPS : 8.15 (-1.33%)
Compass Pathways Launches Proposed $150.0 Million Public Offering

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the launch of a proposed public offering of $150.0 million...

CMPS : 8.15 (-1.33%)
Compass Pathways Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression

Two highly statistically significant positive Phase 3 trials confirm highly differentiated profile for COMP360, demonstrating a level of clinical effect that has historically been extremely difficult to...

CMPS : 8.15 (-1.33%)
Compass Pathways to Announce New Clinical Data from Two Ongoing Phase 3 Trials

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced that tomorrow it will report new clinical data from two ongoing...

CMPS : 8.15 (-1.33%)
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD

FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trial ...

CMPS : 8.15 (-1.33%)
HTGC : 15.30 (-2.24%)
Compass Pathways Establishes Strategic Collaboration with Radial to Innovate Patient Experience and Inform Potential Delivery Model of COMP360

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it is entering into its seventh strategic collaboration,...

CMPS : 8.15 (-1.33%)
Compass Pathways to Host Webinar on Commercial Preparations for Treatment-Resistant Depression (TRD) and Clinical Trial Plans for Post-Traumatic Stress Disorder (PTSD) on January 7, 2026, 10:00am ET

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will host a webinar...

CMPS : 8.15 (-1.33%)
Compass Pathways to Participate in Two Investor Conferences in December

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in...

CMPS : 8.15 (-1.33%)
Compass Pathways to Participate in Stifel 2025 Healthcare Conference

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in...

CMPS : 8.15 (-1.33%)
Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months

Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including...

CMPS : 8.15 (-1.33%)

Business Summary

COMPASS Pathways plc is a mental health care company. It operates principally in New York, USA. COMPASS Pathways plc is headquartered in London, UK.

See More

Key Turning Points

3rd Resistance Point 9.43
2nd Resistance Point 8.97
1st Resistance Point 8.62
Last Price 8.15
1st Support Level 7.81
2nd Support Level 7.35
3rd Support Level 7.00

See More

52-Week High 8.90
Last Price 8.15
Fibonacci 61.8% 6.36
Fibonacci 50% 5.57
Fibonacci 38.2% 4.79
52-Week Low 2.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar